reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
219 |
4. Check minimum number of eventsNone |
219 |
5. Include endpointsNone |
219 |
6. Filter based on genotype QC (FinnGen only) |
219 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ARHTROPAT_REACTIVE
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M02
- Name in latin
- Morbus Reiter
Similar endpoints
↥List of similar endpoints to
Reiter disease
based on the number of shared cases.
Similar with more cases:
- Reactive arthropathies, FINNGEN
- Finngen Rheumatological endpoints
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1810 | 445 | 1350 |
| Only index persons | 1625 | 422 | 1203 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.01 | 0.04 |
| Only index persons | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 43.46 | 44.10 | 43.14 |
| Only index persons | 42.52 | 43.47 | 42.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 219 | 69 | 150 |
| Unadjusted period prevalence (%) | 0.05 | 0.02 | 0.07 |
| Median age at first event (years) | 42.54 | 38.83 | 44.24 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 202
- Matched controls
- 2020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M02.3
ICD-10 Finland
Reiter disease
+∞
273.0
195
*
A07EC01
ATC
sulfasalazine; oral, rectal
35.1
84.4
115
73
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
25.5
76.7
118
105
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
132.0
48.3
50
5
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
14.3
44.4
82
92
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
18.9
39.2
62
46
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
23.7
36.0
52
29
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.4
28.2
53
56
M13.9
ICD-10 Finland
Arthritis, unspecified
9.0
20.8
46
64
H02AB06
ATC
prednisolone; systemic
4.0
19.1
134
671
P01BA02
ATC
hydroxychloroquine; oral
7.6
17.7
43
69
M02.8
ICD-10 Finland
Other reactive arthropathies
+∞
16.9
16
*
13603
ICD-8 Finland
Other and unspecified infective and parasitic diseases, Morbus Reiter, syndroma urethro-oculo-articularis
+∞
16.9
16
*
M45
ICD-10 Finland
Ankylosing spondylitis
14.6
16.2
27
21
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
9.5
15.5
32
39
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
12.8
15.3
27
24
L04AA13
ATC
leflunomide; oral
14.1
14.8
25
20
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
12.8
14.2
25
22
L88
ICPC
Rheumatoid/seropositive arthritis
10.9
13.7
26
27
0993A
ICD-9 Finland
Other venereal diseases, Reiter's disease
+∞
12.6
12
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
8.1
11.7
26
36
S01BA01
ATC
dexamethasone; ophthalmic (corticosteroids, plain)
9.5
11.4
23
27
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
26.8
11.3
15
6
S01FA02
ATC
scopolamine; ophthalmic
24.9
10.4
14
6
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
9.4
9
*
7111L
ICD-9 Finland
Arthropathy associated with infections, Arthropathy associated with Reiter's disease and nonspecific urethritis[UROARTHRITIS, USEAT NIVELET]
+∞
9.4
9
*
3640A
ICD-9 Finland
Disorders of iris and ciliary body, Acute and subacute iridocyclitis
+∞
9.4
9
*
S01BA04
ATC
prednisolone; ophthalmic (corticosteroids, plain)
11.5
9.0
16
15
H02AB07
ATC
prednisone; oral
3.4
8.8
44
151
L04AB01
ATC
etanercept; parenteral
12.3
8.7
15
13
H20.1
ICD-10 Finland
Chronic iridocyclitis
21.1
8.6
12
6
ZX120
NOMESCO Finland
Intravenous
4.1
8.5
34
96
M02.0
ICD-10 Finland
Arthropathy following intestinal bypass
+∞
8.4
8
*
L04AB04
ATC
adalimumab; parenteral
10.7
8.2
15
15
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
15.8
7.8
12
8
N48.1
ICD-10 Finland
Balanoposthitis
8.6
7.8
16
20
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
8.6
7.8
16
20
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
26.1
7.6
10
*
M13.0
ICD-10 Finland
Polyarthritis, unspecified
14.1
7.5
12
9
71490
ICD-8 Finland
Other specified forms of arthritis, Arthritis postinfectiosa NUD
83.0
7.5
8
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
6.7
65
328
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
8.3
6.7
14
18
R4110
NOMESCO Finland
Physiotherapy
2.4
6.7
65
330
M01AC06
ATC
meloxicam; systemic, rectal
2.2
6.7
85
494
M01AH01
ATC
celecoxib; oral (coxibs)
2.8
6.6
45
189
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.6
6.6
29
90
M01CB01
ATC
sodium aurothiomalate; parenteral
14.9
6.5
10
7
M01AE03
ATC
ketoprofen; systemic, rectal
2.1
6.2
88
535
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
159
1016
3.06
12.63
15.8
10.3
4.3
4.1
e9/l
0.46
143
893
22
40
6.00
11.90
2.0
1.3
—
—
—
0
0
181
1276
3.41
11.48
8.7
3.9
10.6
10.8
mm/h
0.11
174
1187
179
1359
2.74
7.94
11.2
7.9
74.8
77.8
u/l
0.54
173
1281
22
58
4.11
7.74
1.4
1.4
2.0
0.0
iu/ml
—
5
12
56
264
2.51
7.46
1.3
1.3
10.0
5.6
u/ml
0.19
21
109
80
473
2.09
6.07
2.9
2.6
354.4
5459.0
umol/l
1.55
73
420
55
281
2.28
6.02
1.2
1.3
17.7
31.2
iu/ml
1.09
18
95
105
711
1.92
5.25
5.0
6.2
1.2
1.2
mmol/l
0.41
96
654
183
1510
2.29
5.03
25.5
16.5
13.7
13.7
%
0.24
183
1487
91
608
1.85
4.59
4.2
2.9
—
—
—
0
0
118
863
1.80
4.36
6.5
4.2
0.0
0.0
estimate
0.00
33
174
49
270
2.05
4.34
3.6
2.7
4.2
1.6
e6/l
0.57
30
150
74
471
1.86
4.30
3.9
2.8
0.2
0.4
e6/l
0.88
59
349
116
853
1.77
4.13
5.1
3.1
0.0
0.0
estimate
0.00
31
173
13
37
3.67
4.12
2.0
1.3
—
—
—
0
0
35
173
2.22
4.08
1.7
1.9
—
—
—
0
0
18
64
2.97
4.06
1.3
1.3
—
—
—
0
0
117
872
1.73
3.89
5.2
3.1
0.0
0.0
estimate
0.00
32
167
107
782
1.72
3.79
5.6
7.7
1.2
1.2
mmol/l
0.92
95
660
11
30
3.81
3.69
1.9
2.8
4.5
4.0
e9/l
0.48
11
30
11
31
3.68
3.53
2.0
2.9
57.0
57.0
%
0.00
11
31
37
200
2.02
3.43
1.8
2.0
—
—
—
0
0
200
1786
2.38
3.38
21.6
13.4
21.2
23.0
mg/l
0.37
176
1409
10
28
3.69
3.23
1.1
1.5
—
—
—
0
0
10
28
3.69
3.23
1.1
1.5
—
—
—
0
0
17
67
2.67
3.21
1.6
2.6
—
—
—
0
0
14
50
2.92
3.15
3.0
1.4
—
—
—
0
0
68
468
1.66
2.86
5.9
3.1
0.0
0.0
estimate
0.00
32
162
193
1725
2.00
2.85
18.1
12.2
87.1
84.6
ml/min/173m2
1.02
182
1429
25
126
2.11
2.79
2.3
2.7
71.6
63.6
ml/min/173m2
0.53
13
60
46
291
1.74
2.62
3.6
2.6
0.6
0.9
e6/l
0.55
27
167
143
1205
1.54
2.36
3.1
3.0
—
—
—
0
0
6
13
4.71
2.28
4.3
4.4
—
—
—
0
0
5
9
5.65
2.22
1.4
1.1
104.7
222.7
iu/ml
—
5
9
91
708
1.49
2.14
4.6
5.1
35.8
36.0
g/l
0.11
85
675
34
210
1.73
2.11
3.2
2.7
4.8
8.2
umol/l
2.27
27
183
29
171
1.80
2.09
4.1
3.1
—
—
—
0
0
89
694
1.48
2.06
5.3
3.1
—
—
—
0
0
51
356
1.56
1.97
1.2
1.2
0.7
0.9
u/ml
0.64
12
102
19
99
2.01
1.97
5.3
10.1
93.4
94.1
%
0.18
19
99
95
757
1.45
1.94
3.6
4.1
—
—
—
0
0
5
13
3.91
1.72
1.0
1.0
—
—
—
0
0
6
19
3.22
1.67
1.0
1.1
—
—
—
0
0
52
383
1.47
1.56
2.2
2.3
—
—
—
0
0
8
33
2.48
1.55
2.3
1.5
—
—
—
0
0
66
511
1.42
1.52
2.4
2.1
1197.9
171.4
u/l
0.48
56
482
12
59
2.09
1.46
5.1
1.8
38.1
38.5
g/l
0.10
12
52
9
39
2.36
1.45
1.6
1.5
—
—
—
0
0
41
294
1.49
1.40
3.1
3.7
0.8
0.8
mmol/l
0.23
36
281
51
382
1.44
1.40
1.8
1.8
0.8
1.3
mg/l
1.57
40
302
5
17
2.98
1.36
1.0
1.1
—
—
—
0
0
195
1831
1.59
1.34
18.0
15.0
139.8
139.7
mmol/l
0.13
195
1783
188
1752
1.52
1.34
4.2
4.3
5.8
6.0
mmol/l
1.53
178
1617
27
182
1.55
1.23
4.6
8.0
0.9
1.0
mmol/l
0.05
18
146
195
1839
1.55
1.22
18.0
15.1
4.0
4.0
mmol/l
1.33
195
1789
6
26
2.34
1.19
2.0
3.7
2.6
3.9
nmol/l
—
6
26
8
39
2.09
1.16
2.1
1.6
—
—
—
0
0
8
39
2.09
1.16
1.3
1.2
—
—
—
0
0
12
65
1.90
1.16
5.1
1.9
3.2
3.0
g/l
0.26
12
56
203
1937
1.66
1.13
22.5
15.4
79.6
80.4
umol/l
0.13
203
1937
15
89
1.74
1.11
3.8
7.4
23.4
24.7
mmol/l
0.93
15
89
196
1858
1.52
1.10
5.0
4.8
2.8
2.8
mmol/l
0.01
190
1731
65
528
1.33
1.09
3.6
3.7
2.3
2.3
mmol/l
0.05
60
471
75
625
1.30
1.05
2.2
1.9
94.1
93.4
pmol/l
0.06
43
339
12
69
1.78
0.98
5.1
1.9
4.3
3.7
g/l
1.01
12
54
12
69
1.78
0.98
5.1
1.9
7.0
7.3
g/l
0.28
12
57
12
69
1.78
0.98
5.1
1.9
—
—
—
0
0
5
23
2.20
0.98
1.0
1.1
—
—
—
0
0
25
175
1.48
0.98
1.4
1.3
—
—
—
0
0
169
1573
1.33
0.97
4.0
4.2
1.7
1.9
mu/l
1.23
159
1426
0
32
0.00
0.96
0.0
1.4
—
—
—
0
0
38
291
1.37
0.93
3.6
3.5
318.5
277.2
ng/l
0.07
31
217
6
29
2.10
0.90
1.3
1.2
—
—
—
0
0
8
42
1.94
0.89
1.0
1.3
—
40.8
—
0
6
8
43
1.89
0.88
1.1
1.4
633.5
208.9
e6/l
—
8
35
17
112
1.56
0.88
1.4
1.6
—
—
—
0
0
46
367
1.32
0.87
2.2
1.9
2.9
3.3
mg/l
0.62
39
322
79
678
1.26
0.86
3.2
3.5
31.6
35.4
ng/l
0.13
49
451
8
46
1.77
0.83
1.5
1.3
—
—
—
0
0
6
32
1.90
0.82
1.2
3.0
—
945.4
—
0
5
14
210
0.64
0.82
6.8
7.6
—
—
—
0
0
15
98
1.57
0.81
2.4
1.6
—
—
—
0
0
11
66
1.70
0.80
2.4
3.4
—
—
—
0
0
39
308
1.32
0.79
1.4
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
26
194
1.39
0.75
1.9
1.8
—
—
—
0
0
7
38
1.87
0.74
1.9
1.3
—
—
—
0
0
7
39
1.82
0.73
1.9
7.8
—
161.5
—
0
8
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
5
26
1.94
0.71
2.2
2.1
—
—
—
0
0
5
26
1.94
0.71
3.2
3.5
—
—
—
0
0
20
146
1.41
0.66
3.3
4.2
1.0
1.8
mmol/l
0.54
12
119
54
457
1.24
0.65
1.7
1.7
1.4
1.5
mmol/l
0.74
47
382
22
164
1.38
0.65
3.0
5.0
7.2
32.6
ug/l
0.49
17
136
178
1696
1.26
0.65
5.5
5.4
37.9
39.9
mmol/mol
2.89
173
1596
36
290
1.29
0.65
2.2
2.1
1.6
1.5
%
0.32
29
259
0
22
0.00
0.59
0.0
2.2
—
22.0
—
0
7
33
267
1.28
0.58
1.8
1.9
—
—
—
0
0
15
108
1.42
0.54
1.6
1.4
—
—
—
0
0
6
39
1.55
0.53
1.8
1.6
—
—
—
0
0
78
700
1.18
0.52
3.7
2.6
251.5
162.4
ug/l
0.79
73
649
134
1257
1.17
0.51
3.5
3.6
14.7
14.8
pmol/l
0.12
123
1141
189
1828
1.25
0.49
4.3
4.3
1.4
1.4
mmol/l
0.14
183
1702
24
191
1.29
0.49
2.0
1.8
—
—
—
0
0
10
68
1.49
0.48
4.3
3.5
6.6
201.9
u/ml
—
5
55
43
371
1.20
0.44
2.2
1.6
28.3
20.3
nmol/l
0.38
37
323
184
1781
1.21
0.43
3.9
3.9
1.4
1.4
mmol/l
0.05
176
1653
0
15
0.00
0.41
0.0
1.9
—
13.2
—
0
15
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
5
34
1.48
0.40
1.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.2
—
16.3
—
0
18
11
80
1.39
0.39
1.0
1.0
—
—
—
0
0
64
701
0.88
0.35
4.0
3.8
24.2
21.5
%
0.57
29
297
140
1337
1.13
0.35
4.0
3.1
56.3
50.3
u/l
0.43
134
1266
6
46
1.31
0.33
1.0
1.3
—
—
—
0
0
7
56
1.26
0.29
5.3
2.7
83.1
157.5
mg/l
—
7
43
7
56
1.26
0.29
5.3
2.7
27.5
34.6
mg/l
—
7
43
5
75
0.66
0.26
1.6
1.8
4.0
5.3
mg/l
—
5
55
5
40
1.26
0.22
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
36
327
1.12
0.21
1.7
1.7
419.7
450.8
pmol/l
0.37
29
283
0
14
0.00
0.20
0.0
1.0
—
39.6
—
0
7
0
14
0.00
0.20
0.0
1.0
—
505.7
—
0
7
6
49
1.23
0.20
1.0
1.1
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
9
81
1.12
0.15
1.0
1.3
—
—
—
0
0
7
88
0.79
0.15
1.7
2.1
—
—
—
0
0
168
1704
0.94
0.11
23.5
13.5
41.6
41.3
%
0.24
137
1310
10
87
1.16
0.09
1.4
1.9
221.9
251.9
pmol/l
—
10
82
5
47
1.07
0.09
1.2
1.9
—
—
—
0
0
6
58
1.04
0.08
1.5
2.1
—
—
—
0
0
6
71
0.84
0.08
3.2
1.5
392.0
259.3
mu/l
—
6
65
6
72
0.83
0.08
1.8
2.1
—
—
—
0
0
6
73
0.82
0.07
2.7
3.9
46.0
51.8
%
—
6
73
205
2037
1.10
0.07
30.7
19.4
138.5
139.7
g/l
0.52
205
2007
16
149
1.08
0.05
6.3
8.4
9.4
9.3
mmol/l
0.01
16
144
53
517
1.03
0.04
2.8
2.7
0.5
0.7
ug/l
2.62
36
313
20
196
1.02
0.00
1.7
1.8
—
—
—
0
0
88
876
1.01
0.00
3.7
4.2
1.6
2.2
ug/l
0.76
79
792
0
8
0.00
0.00
0.0
4.3
—
—
—
0
0
0
8
0.00
0.00
0.0
4.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
21.7
—
0
7
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
90.8
—
0
6
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint REITER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.516 [1.12, 2.06] | 0.008 |
| Birth year | 0.999 [0.99, 1.01] | 0.892 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 387 females with REITER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.526 [1.28, 1.82] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 189 out of 1071 males with REITER died.
Mortality risk
Mortality risk for people of age
years, who have REITER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.168% | 0.209% |
| 5 | 1.11% | 1.463% |
| 10 | 2.728% | 3.843% |
| 15 | 5.054% | 7.025% |
| 20 | 9.186% | 12.038% |
Relationships between endpoints
↥Index endpoint: REITER – Reiter disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data